Skip to main content
1150 search results for:

Clinical trial 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 16-11-2020 | JAK inhibitors | News | Article

    Meta-analysis queries VTE risk associated with JAK inhibitors in clinical trials

    A meta-analysis of randomized controlled trials has found no significant association between Janus kinase inhibitor use and the risk for venous thromboembolism among patients with immune-mediated inflammatory diseases.

  2. 14-11-2022 | ACR 2022 | Conference coverage | Article

    Phase 3 trial supports add-on telitacicept for SLE

    Addition of the recombinant fusion protein telitacicept to standard care may reduce disease activity and is well tolerated in people with systemic lupus erythematosus, research suggests.

  3. 16-11-2020 | JAK inhibitors | Highlight | Teaser
    medwireNews top story

    Meta-analysis queries VTE risk associated with JAK inhibitors in clinical trials

    A meta-analysis of randomized controlled trials has found no significant association between Janus kinase inhibitor use and the risk for venous thromboembolism among patients with immune-mediated inflammatory diseases.

  4. 02-10-2020 | COVID-19 | Highlight | Teaser
    Spotlight on: Repurposing rheumatology drugs for COVID-19

    PATCH trial shows ‘no clinical benefit’ of hydroxychloroquine for COVID-19 prophylaxis

    Prophylactic use of hydroxychloroquine does not reduce the risk for SARS-CoV-2 infection among hospital-based healthcare workers at high risk for exposure, suggest findings from a randomized controlled trial.

  5. 30-09-2020 | COVID-19 | News | Article

    PATCH trial shows ‘no clinical benefit’ of hydroxychloroquine for COVID-19 prophylaxis

    Prophylactic use of hydroxychloroquine does not reduce the risk for SARS-CoV-2 infection among hospital-based healthcare workers at high risk for exposure, suggest findings from a randomized controlled trial.

  6. 18-07-2022 | Systemic lupus erythematosus | News | Article

    LOTUS trial suggests no benefit of ustekinumab in SLE

    Development of ustekinumab as a potential therapeutic option for systemic lupus erythematosus has been terminated following an interim analysis of the phase 3 LOTUS trial, which demonstrated no benefit of the IL-12/23 inhibitor in this patient population.

  7. 12-07-2022 | Rheumatoid arthritis | News | Article

    Background methotrexate may boost placebo response in RA trials

    Background therapy with methotrexate may partly explain placebo responses observed in rheumatoid arthritis clinical trials, study findings indicate.

  8. 27-06-2022 | Image

    A quick guide to the phase 3 trials of bimekizumab in spondyloarthritis

    © Bacho Foto / Fotolia
  9. 30-06-2022 | COVID-19 | News | Article

    VROOM trial: Pausing methotrexate doubles antibody response to COVID-19 booster vaccine

    Holding methotrexate treatment for 2 weeks following administration of a booster dose of vaccines against SARS-CoV-2 significantly improves the humoral immune response to vaccination, suggest findings from a randomized controlled trial.

  10. 25-05-2022 | Bimekizumab | Feature | Article
    Updated June 2022

    A quick guide to the phase 3 trials of bimekizumab in spondyloarthritis

    Summary of the phase 3 trials investigating the IL-17A/IL-17F inhibitor bimekizumab in patients with ankylosing spondylitis, nonradiographic axial spondyloarthritis, or psoriatic arthritis.

  11. play
    14-06-2022 | EULAR 2022 | Conference coverage | Video

    The BE MOBILE 1 and 2 trials of bimekizumab in axSpA

    Désirée van der Heijde outlines the findings of two phase 3 trials demonstrating that bimekizumab may be beneficial for patients with nonradiographic axial spondyloarthritis or ankylosing spondylitis.

  12. 04-06-2022 | EULAR 2022 | Conference coverage | Article

    Bimekizumab beneficial for psoriatic arthritis in phase 3 trials

    Bimekizumab has shown positive efficacy and safety results in the BE COMPLETE and BE OPTIMAL phase 3 psoriatic arthritis trials.

  13. 01-06-2022 | EULAR 2022 | Conference coverage | Article

    BE MOBILE trials support bimekizumab for the treatment of axSpA

    Both trials were presented at the EULAR 2022 Congress in Copenhagen, Denmark.

  14. play
    07-06-2022 | EULAR 2022 | Conference coverage | Video

    The BE COMPLETE and BE OPTIMAL trials of bimekizumab in PsA

    Joseph Merola talks about the BE COMPLETE and BE OPTIMAL trials, which showed that the dual IL-17A/IL-17F inhibitor bimekizumab is a promising treatment option for psoriatic arthritis patients with and without prior exposure to TNF inhibitors.

  15. 03-06-2022 | EULAR 2022 | Conference coverage | Article

    OKINADA trial: No improvement in knee osteoarthritis symptoms with TNF inhibition

    The tumor necrosis factor inhibitor adalimumab does not improve pain or function in people with knee osteoarthritis, indicate phase 2 trial results.

  16. 20-11-2019 | Rheumatoid arthritis | Highlight | Teaser
    medwireNews top story

    Insufficient diversity in RA clinical trial populations

    A systematic review has identified insufficient representation of people from racial minority groups, older individuals, and men in randomized controlled trials investigating treatments for rheumatoid arthritis.

  17. 20-11-2019 | Rheumatoid arthritis | News | Article

    Insufficient diversity in RA clinical trial populations

    A systematic review has identified insufficient representation of people from racial minority groups, older individuals, and men in randomized controlled trials investigating treatments for rheumatoid arthritis.

  18. 12-04-2022 | Vasculitis | News | Article

    ALEVIATE trial: Alemtuzumab may warrant further investigation for refractory vasculitis

    Findings from a phase 2b trial suggest that treatment with the anti-CD52 antibody alemtuzumab may be beneficial for some patients with primary systemic vasculitis and an inadequate response to conventional therapies.

  19. 01-04-2022 | Lupus nephritis | News | Article

    Trial supports tacrolimus as an alternative to cyclophosphamide for lupus nephritis

    Phase 3 trial results suggest that the calcineurin inhibitor tacrolimus may represent an alternative option to cyclophosphamide for the initial treatment of lupus nephritis.

  20. 14-03-2022 | Giant cell arteritis | News | Article

    Phase 2 trial supports further investigation of JAK inhibitors for giant cell arteritis

    Findings from a proof-of-concept trial provide preliminary evidence to suggest that the JAK inhibitor baricitinib is well tolerated and may have efficacy for the treatment of relapsing giant cell arteritis.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.